Saliva as an alternative specimen to nasopharyngeal swabs for COVID-19 diagnosis: Review

Leah McPhillips† and John MacSharry1,2,3,*

Abstract
Almost 2 years ago, the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was discovered to be the causative agent of the disease COVID-19. Subsequently, SARS-CoV-2 has spread across the world infecting millions of people, resulting in the ongoing COVID-19 pandemic. The current ‘gold standard’ for COVID-19 diagnosis involves obtaining a nasopharyngeal swab (NPS) from the patient and testing for the presence of SARS-CoV-2 RNA in the specimen using real-time reverse transcription PCR (RT-qPCR). However, obtaining a NPS specimen is an uncomfortable and invasive procedure for the patient and is limited in its applicability to mass testing. Interest in saliva as an alternative diagnostic specimen is of increasing global research interest due to its malleability to mass testing, greater patient acceptability and overall ease of specimen collection. However, the current literature surrounding the sensitivity of saliva compared to NPS is conflicting. The aim of this review was to analyse the recent literature to assess the viability of saliva in COVID-19 diagnosis. We hypothesize that the discrepancies in the current literature are likely due to the variations in the saliva collection and processing protocols used between studies. The universal adaptation of an optimised protocol could alleviate these discrepancies and see saliva specimens be as sensitive, if not more, than NPS for COVID-19 diagnosis. Whilst saliva specimens are more complimentary to mass-testing, with the possibility of samples being collected from home, the RT-qPCR diagnostic process remains to be the rate-limiting step and therefore interest in salivary rapid antigen tests, which negate the wait-times of RT-qPCR with results available within 15–30 min, may be an answer to this.

INTRODUCTION
The on-going COVID-19 pandemic has drastically impacted all corners of the globe. The rise of new and more infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and with the majority of the world population still to receive vaccination against the virus, testing, social-distancing, face-coverings, self-isolation/quarantining and regional/country-wide lockdowns remain to be the modus operandi in controlling viral spread [1, 2]. For COVID-19 diagnosis, the World Health Organization (WHO) currently recommends real-time reverse transcription PCR (RT-qPCR) to detect SARS-CoV-2 RNA from nasopharyngeal and/or oropharyngeal swabs (NPS and OPS), with NPS being the reference standard for routine diagnosis [3]. This is primarily because NPS have been established as the specimen of choice for the diagnosis of other viral respiratory infections [4, 5]. However, NPS have a number of limitations including the requirement of trained health-care workers (HCWs), personal protection equipment (PPE), swabs and viral transport media (VTM) for specimen collection which has resulted in global supply shortages and testing ‘bottlenecks’ [6–8]. NPS collection is an invasive and uncomfortable procedure which can lead to physical resistance thus affecting specimen quality, cause bleeding in patients with thrombocytopenia and ultimately makes individuals less likely to return for future/repeated testing [9–12]. This can also impact NPS’s applicability to COVID-19 surveillance, as
repeated swabbing can leave patients with symptoms such as nosebleeds, headaches, rhinorrhea and general nasal discomfort that can last up to 24 h [13]. Additionally, NPS collection puts HCWs at high risk of nosocomial infection as specimen collection can induce coughing/sneezing in patients [14]. Therefore, alternatives to NPS have become of global research interest, where in particular saliva has come to the fore. Saliva offers a number of advantages over the current reference standard including the less invasive nature of specimen collection creates greater patient acceptability and thus individuals are more likely to get tested and give repeated specimens [15]. It does not require close-contact with HCWs thus reducing the risk of nosocomial infection and demands for PPE. Saliva collection also has the potential to be self-administered from home and is not affected by supply shortages as only a sterile container is required for specimen collection [16]. Currently, the WHO does not recommend saliva as the only specimen for routine diagnosis, but it is used for COVID-19 surveillance in Hong Kong and parts of the USA where a number of saliva-based assays have been granted Emergency Use Authorisation (EUA) by the US Food and Drug Administration (FDA), where it has in particular been adopted to carry out surveillance in educational institutes [17–24]. In this review the methods of saliva specimen collection, transport and processing, its accuracy compared to NPS especially for mild/asymptomatic patients, its potential to be implemented for mass screening/surveillance and the limitations both of saliva as a diagnostic tool and the corresponding literature will be discussed.

MAIN
Saliva specimen collection, transportation and storage and their impact on specimen sensitivity

There are a number of possible sources of SARS-CoV-2 in saliva [25]. It was initially uncertain whether SARS-CoV-2 directly infected epithelial cells in the oral cavity although the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), and both the transmembrane serine protease (TMPRSS) receptors, TMPRSS2 and TMPRSS4, which are required for spike protein cleavage to allow receptor binding and membrane-fusion to facilitate viral entry into the host cell, are highly expressed on the surface of the minor salivary gland epithelial cells and the oral mucosa [26–32]. Whilst furthermore, SARS-CoV, the causative agent of the SARS outbreak in 2002–2004, was found to infect salivary gland cells in a Rhesus macaque model [33]. It has recently been confirmed through both COVID-19 patient autopsies and mildly symptomatic COVID-19 outpatient samples that SARS-CoV-2 can directly infect the epithelial cells of the salivary glands and oral mucosa [34]. This not only explains symptoms such as loss of taste, dry mouth etc. experienced by many COVID-19 patients but also further strengthens the argument for using saliva as a COVID-19 diagnostic by providing a definitive source of the virus in saliva. Other potential sources of SARS-CoV-2 in saliva include entry by the exchange of fluids, liquid droplets and/or the mucociliary escalator from the nasal cavity and/or the respiratory tract [35]. SARS-CoV-2 present in the blood could also enter saliva via gingival crevicular fluid and indeed has been detected in gingival crevicular fluid, or by salivary epithelial cells transporting blood-borne virions across the epithelial barrier by endocytosis and exocytosis [36, 37].

A large number of studies have been conducted since the COVID-19 pandemic began to determine the efficacy of saliva for COVID-19 diagnosis against the reference standard NPS (Table 1). The results from these studies have varied with some finding saliva to be equal to or more sensitive than NPS [38–48] whereas others found it to be less sensitive [49–61]. The specimen collection protocol is one factor that could result in the inconsistencies between these studies (Fig. 1). The method of saliva collection in these studies has varied from posterior oropharyngeal swabbing (POPS), or deep throat saliva, obtained by the patient clearing their throat [15, 19, 35, 39, 40, 42, 43, 56, 62, 63] (Fig. 2), to saliva from the oral cavity obtained by spitting/drooling [38, 47, 51, 52, 55, 59, 64–71] (Fig. 2), swabs of the saliva glands [45, 57, 72, 73] and others not specifying the collection method [41, 49, 50, 53, 54, 58]. Currently, it is unclear whether POPS or oral saliva is the more sensitive specimen, although POPS likely has a higher viral load, particularly in the early morning, as it has possibly mixed with nasopharyngeal and bronchopulmonary secretions which move towards the posterior oropharyngeal region when individuals are lying down during sleep [35] (Fig. 2). However, POPS requires coughing/throat-clearing for specimen collection and therefore results in aerosolization of potentially contaminated aerosols and dry coughs are reported in around 80% of COVID-19 patients which could result in difficulty in specimen collection [66, 74]. Additionally, POPS is more likely to be more mucus-rich and viscous which can create difficulties in saliva specimen processing (discussed further below), which is likely why [15, 35, 40, 56] added VTM to their POPS specimens. To the best of our knowledge, no study has directly compared the sensitivity between different saliva collection methods and therefore future research is needed to identify the best collection method for optimum saliva sensitivity [75].

Some studies collected saliva in the early morning [19, 35, 38, 39, 55, 56] when viral load is believed to be highest and/or asked patients to refrain from eating/drinking/smoking and/or oral hygiene from 0.5 h to overnight before specimen collection [19, 35, 38, 39, 43, 45, 47, 48, 54–56, 60, 62, 65, 70, 71, 76] as this has been demonstrated to increase SARS-CoV-2 concentration in saliva [77–79] and for example mouth wash has been shown to reduce the SARS-CoV-2 viral load in saliva specimens [80, 81]. Whilst one study noted that they did not observe a difference in saliva specimen sensitivity when patients had eaten/drank/smoked/used oral hygiene within 30 min of sample collection [46], the general consensus in the majority of studies is that patients should avoid eating/drinking/smoking and/or oral hygiene before providing a saliva sample. This adds an extra layer of variability in saliva sample sensitivity compared to NPS, as such recommendations are not required nor have been shown to influence NPS specimen sensitivity (Fig. 1, Table 2).
Table 1. Studies that have evaluated the specificity of saliva specimens to NPS/other respiratory specimens. Adapted from [131] and [105]

| Study and reference | Date | No. of paired samples | Patient information | Respiratory sample | SARS-CoV-2 target genes | Saliva sample (RT-qPCR) Sensitivity (%) | Discordance | Saliva specimen collection method | Ct value higher in saliva than respiratory sample |
|---------------------|------|-----------------------|---------------------|-------------------|-------------------------|----------------------------------------|------------|----------------------------------|-----------------------------------------------|
| To et al. [15]      | Feb-20 | 12                    | Confirmed hospitalised COVID-19 patients | NPS or sputum | S gene | 11/12, 91.7% | one NPS/sputum only | Self-collected POPS, 2 ml of VTM added | Not mentioned |
| Chen et al. [57]    | Mar-20 | 31                    | Confirmed COVID-19 patients ~ four had severe COVID-19 | OPS | N gene and ORF1ab | 4/31, 12.9% | 27 OPS only | Saliva was collected from the opening of the salivary glands | Not mentioned |
| Wyllie et al. [38]  | Apr-20 | 1. 29 2. 33           | 1. Severe hospitalised COVID-19 patients 2. Asymptomatic at risk HCWs | NPS | N gene (N1 and N2) | Not mentioned, just stated saliva was more sensitive | two of the HCWs, two samples were saliva positive and all were NPS negative | Early morning before eating/brushing - self-collected by repeated spitting. Stored at room temperature. | No |
| Williams et al. [52]| Apr-20 | 522                   | Unconfirmed ambulatory outpatients | NPS | Not mentioned | 30/39, 84.62% | one saliva only, six NPS only | Asked to pool saliva in mouth for 1–2 mins and then spit. A 1:1 ratio of Amies medium was added after. | Yes |
| Kojima et al. [132]| Apr-20 | 45                    | Unconfirmed patients - 21 were symptomatic | NPS | N gene (N1 and N2) | 26/29 98.7% | Not mentioned | Clinician-supervised oral fluid swab specimens. Asked to enhance specimen by coughing before collection. | Yes |
| Becker et al. [58]  | May-20 | 1. 88 2. 24           | 1. symptomatic 2. convalescent | NPS | ORF1ab, S and N genes | 1. 69.2% 2. 20–50% | Not mentioned | Not mentioned but added stabilising solution | Not mentioned |
| McCormick-Baw et al. [64] | May-20 | 156                   | Hospitalised confirmed COVID-19 patients | NPS | N2 and E gene | 47/49, 95.92% | one saliva only, three NPS only | Not mentioned but no preservative added | Yes |
| To et al. [35]      | May-20 | 23                    | Hospitalised confirmed COVID-19 patients | NPS or sputum | RdRP gene | 20/23, 86.9% | three NPS/sputum only | POPS - early morning before eating/brushing - VTM added | Not mentioned |
| Pasomsub et al. [66]| May-20 | 200                   | Symptomatic unconfirmed patients | NPS and OPS | N gene and ORF1ab | 16/19, 84.21% | two saliva only, one NPS only | Oral cavity saliva sample, collected without inducing coughing/throat clearing | Yes |
| Iwasaki et al. [68] | Jun-20 | 76                    | Mild-moderate symptoms of which 10 were confirmed COVID-19 patients | NPS | N gene | 9/10, 90% | one saliva only, one NPS only | Self-collected oral saliva | Yes |

Continued
| Study and reference | Date  | No. of paired samples | Patient information | Respiratory sample | SARS-CoV-2 target genes | Saliva sample (RT-qPCR) Sensitivity (%) | Discordance | Saliva specimen collection method | Ct value higher in saliva than respiratory sample |
|---------------------|-------|-----------------------|---------------------|-------------------|-------------------------|-----------------------------------------|-------------|---------------------------------|-----------------------------------------------|
| Jamal *et al.* [55] | Jun-20 | 52                    | Confirmed hospitalised COVID-19 patients | NPS              | RdRP, E and N gene    | 51/47, 77%                             | five saliva only, 11 NPS only | Asked to spit one teaspoon of saliva - 2.5 ml of PBS added, frozen at −80 °C | Mean difference not statistically significant |
| Chen *et al.* [56] | Jun-20 | 58                    | Confirmed COVID-19 patients | NPS              | N2 and E genes        | 52/58, 89.7%                           | three saliva only, six NPS only | POPS - early morning before eating/brushing - 2 ml VTM added | Yes |
| Wong *et al.* [19] | Jun-20 | 229                   | 229 paired NPS-saliva samples from 95 patients. 51 were COVID-19 confirmed of which seven were asymptomatic. | NPS              | E gene                 | 14/159, 88.7%                           | 37 saliva only, 18 NPS only | POPS - early morning before eating/brushing - 1 ml of VTM added | Not mentioned |
| Chau *et al.* [53] | Jun-20 | 30                    | Confirmed COVID-19 patients – 13 were asymptomatic and 17 were symptomatic. | NPS              | E gene                 | 20/27, 74%                             | one saliva only, seven NPS only | Not mentioned | Yes |
| Griesmer *et al.* [54] | Jun-20 | 463                   | 1. 236 unconfirmed asymptomatic and symptomatic patients. 2. 227 unconfirmed symptomatic patients | NPS              | N gene (N1)      | 1. 6/12, 50% 2. 81/93, 87.1% | 1) six NPS only 2) two saliva only, 12 NPS only | Not mentioned. Asked not to eat/drink/smoke 30 mins before saliva collection. Stored at 4 °C before processing | Yes |
| Skolimowska *et al.* [67] | Jun-20 | 132                   | Unconfirmed symptomatic HCW's and their household contacts | Combined NPS and OPS | ORF1ab and ORF8 | 15/18, 83.3%                           | one saliva only, three NPS only | Self-collected, patients asked to spit without inducing coughing | Yes |
| Azzi *et al.* [69] | Jul-20 | 25                    | Confirmed severe COVID-19 patients | NPS              | 5' UTR                 | 25/25, 100%                           | n/a | Oral saliva collected by drooling technique - or collected by pipette if patient was intubated | Not mentioned |
| Leung *et al.* [40] | Jul-20 | 95                    | 95 paired saliva-NPS samples from 62 patients of which 29 were confirmed COVID-19 and 33 were COVID-19 negative patients | NPS              | E gene                 | 51/61, 83.6%                           | 13 saliva only, seven NPS only | Deep throat saliva (POPS) - 2 ml of VTM added | Not mentioned |
| Study and reference          | Date   | No. of paired samples | Patient information                                                                 | Respiratory sample | SARS-CoV-2 target genes | Saliva sample (RT-qPCR) Sensitivity (%) | Discordance | Saliva specimen collection method                                                                 | Ct value higher in saliva than respiratory sample |
|-----------------------------|--------|-----------------------|-------------------------------------------------------------------------------------|--------------------|-------------------------|----------------------------------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| Nagura-Ikeda et al. [82]    | Jul-20 | 103                   | Confirmed COVID-19 of which 15 asymptomatic and 88 symptomatic                     | NPS or OPS         | N1 and N2 genes         | 84/103, 81.6%                        | Not mentioned | Self-collected oral saliva, PBS added - no restriction on time of collection or of eating before collection                     | Not mentioned                                  |
| Byrne et al. [85]           | Jul-20 | 145                   | Unconfirmed symptomatic outpatients                                                  | Nasal/throat swabs | Not mentioned            | 20/23, 86.9%                        | three saliva only, three nasal/throat only | Pooled saliva and spat into sterile container – approximately 200 µL were collected and stored at −80 °C | Not mentioned                                  |
| Landry et al. [70]          | Jul-20 | 124                   | Unconfirmed symptomatic outpatients                                                  | NPS                | N gene (N1 and N2)      | 30/35, 85.7%                        | two saliva only, five NPS only            | Pooled saliva in mouth then spat into sterile container. Asked not to eat/drink 30 min before collection | Yes                                             |
| Caulley et al. [50]         | Aug-20 | 1939                  | High risk asymptomatic and mildly symptomatic unconfirmed patients                  | NPS or OPS         | E gene                  | 48/70, 68.6%                        | 14 saliva only, 22 NPS only             | Not mentioned                                  | Not mentioned                                  |
| Kim et al. [14]             | Aug-20 | 15                    | Confirmed hospitalised COVID-19 patients, both asymptomatic and symptomatic         | NPS or OPS         | Not mentioned            | 34/53, 64% (multiple samples taken) | Not mentioned                                  | Oral cavity saliva - patients asked to spit into sterile container. Mean difference not statistically significant |                                                 |
| Migueres et al. [51]        | Aug-20 | 123                   | Confirmed COVID-19 patients both asymptomatic and symptomatic 9 were hospitalised  | NPS                | RdRP gene               | 34/41, 82.93%                       | three saliva only, seven NPS only        | Patients asked to swirl saliva in mouth for at least 30 s and then spit into sterile container | Yes                                             |
| Rao et al. [39]             | Aug-20 | 217                   | Confirmed asymptomatic male COVID-19 patients                                       | NPS                | E and RdRP genes        | 149/146, 93.1%                      | 76 saliva only, 11 NPS only             | Deep throat saliva (POPS) collected early morning before eating/brushing. Stored at room temperature before processing | No                                              |
| Bhattacharya et al. [99]    | Sep-20 | 74                    | Unconfirmed COVID-19 patients with mild to moderate symptoms                        | NPS                | ORF1 and E genes        | 48/53, 90.5%                        | five NPS only                            | Not mentioned                                  | No                                              |
| Study and reference | Date     | No. of paired samples | Patient information                                                                 | Respiratory sample | SARS-CoV-2 target genes | Saliva sample (RT-qPCR) Sensitivity (%) | Discordance                                                                 | Saliva specimen collection method                                                                 | Ct value higher in saliva than respiratory sample |
|---------------------|----------|-----------------------|--------------------------------------------------------------------------------------|--------------------|-------------------------|------------------------------------------|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Yokota et al. [41]  | Sep-20   | 1. 161 2. 1763        | 1) Asymptomatic close-contact cohort 2) Asymptomatic airport quarantine cohort        | NPS                | N gene (N2 primer)      | 1. 44/47, 93.6% 2. 4/5, 80% 3. Total: 48/52, 92% | 1. six saliva only. three NPS only 2. one NPS only | Not mentioned but stored at 4°C                                                                                       | Mean difference not statistically significant                                           |
| Moreno-Contreras et al. [133] | Sep-20   | 253                   | Unconfirmed symptomatic outpatients 1. 182 had a saliva and OPS sample taken 2. 71 had saliva and both NPS and OPS | NPS and/or OPS     | E gene                  | 1. 69/80, 86.2% 2. 25/34, 73.5%          | 1. 28 saliva only, 11 OPS only 2. six saliva only, nine NPS/OPS only | Self-collected, patients asked to spit repeatedly until 2–3 ml was collected. No VTM or stabilisers added | No                                                                                          |
| Nacher et al. [49]  | Sep-20   | 776                   | Unconfirmed - 39% were asymptomatic and 61% were mildly symptomatic                   | NPS                | RdRP, E and N genes    | 86/162, 53%                                    | ten saliva only, 76 NPS only | Not mentioned but pooled saliva samples from multiple patients for testing                                          | Not mentioned                                                                                     |
| Zhu et al. [98]     | Sep-20   | 944                   | 12 separate cohorts                                                                  | NPS                | Not mentioned           | 397/442, 89.82%                                | 15 saliva only, 60 NPS only | Not mentioned                                                                                                  | Not mentioned                                                                                     |
| Fan et al. [62]     | Oct-20   | 65                    | Confirmed COVID-19 patients, of which 42 had severe COVID-19                           | Throat/nasal swabs | ORF1ab                  | 37/42, 88.09%                                    | Not mentioned                                                                                          | POPPS. Patients asked not to eat/drink at least 30 mins before specimen collection               | No                                                                                              |
| Hanson et al. [123] | Oct-20   | 354                   | Unconfirmed symptomatic patients                                                      | NPS                | RdRP gene               | 81/86, 84.2%                                    | six saliva only, five NPS only | Pooled saliva in mouth and spit repeated until approximately 1 ml was collected - asked not to induce coughing | Not mentioned                                                                                     |
| Berenger et al. [59] | Oct-20   | 75                    | Confirmed COVID-19 patients, of which 9.5% were hospitalised                          | NPS or OPS         | E and RdRP genes        | 58/75, 77.3%                                    | six saliva only, 11 NPS only | Pooled saliva in mouth for 1–2 mins and then spit, and 3 ml of UTM was added                                  | Yes                                                                                              |
| Senok et al. [71]   | Oct-20   | 401                   | Unconfirmed symptomatic and asymptomatic patients                                     | NPS                | RdRP and N genes        | 28/35, 80%                                     | nine saliva only, seven NPS only | Asked to pool saliva in mouth for 1–2 min and then spit saliva into sterile container. No transport media was added and patients were asked not to eat/drink/smoke at least an hour before hand. | Mean difference not statistically significant                                                                 |
| Study and reference | Date   | No. of paired samples | Patient information                                                                 | Respiratory sample | SARS-CoV-2 target genes | Saliva sample (RT-qPCR) Sensitivity (%) | Discordance | Saliva specimen collection method                                                                 | Ct value higher in saliva than respiratory sample |
|---------------------|--------|-----------------------|--------------------------------------------------------------------------------------|--------------------|-------------------------|-----------------------------------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| Vaz et al. [84]     | Oct-20 | 149                   | Symptomatic HCWs and confirmed COVID-19 patients                                     | NPS                | RdRP and E genes        | 69/73, 94.5% two saliva only, four NPS only | Not mentioned | Saliva was diluted with PBS and transported at 4°C and stored at −80°C                                                                                         |                                                  |
| Procop et al. [42]  | Nov-20 | 216                   | Unconfirmed symptomatic patients                                                     | NPS                | N gene (N1, N2 and N3 primers) | 100%, 38/38 N/A POPS - Enhanced saliva sample by strong sniff and elicited cough - no transport media added | Yes         |                                                                                                                                                                  |                                                  |
| Kandel et al. [83]  | Nov-20 | 432                   | Unconfirmed outpatients - 30% asymptomatic                                          | NPS                | E gene                  | 42/46, 91% three saliva only, four NPS only | Not mentioned | Pooled saliva in mouth for 60secs. Asked to collected as much saliva as they could, up to 5 ml - no VTM added, stored at 4°C until processing. | Yes                                              |
| Yee et al. [65]     | Nov-20 | 300                   | Unconfirmed symptomatic and asymptomatic and 27 were known COVID-19 patients        | NPS                | N, S and ORF1ab genes   | 79/97, 81.4% ten saliva only, 18 NPS only | Not mentioned | Asked to rub cheeks to stimulate saliva and then spit without coughing - asked to avoid eating/drinking/smoking at least 30 mins before collection. | Yes                                              |
| Matic et al. [86]   | Nov-20 | 74                    | Symptomatic unconfirmed patients - included patients from long-term care facilities, HCWs and household close-contacts | NPS                | E gene                  | 15/21, 71.4% one saliva only, six NPS only | Not mentioned | Asked to pool saliva in their mouth and spit approximately 1 ml into a sterile container - stored at room temperature with no VTM added | Not mentioned                                      |
| Braz-Silva et al. [45] | Dec-20 | 201                   | Unconfirmed symptomatic patients                                                      | NOP (nasal and oropharyngeal swab combined) | E and S genes | 55/70, 78.6% 18 saliva only, 15 NOP only | No          | Saliva was collected using the Salivette cotton pad device where patients were asked to chew down on cotton pad carefully for 1 min. Samples were collected in the morning before eating and were stored at 4°C until processing. |                                                  |
| Study and reference | Date | No. of paired samples | Patient information | Respiratory sample | SARS-CoV-2 target genes | Saliva sample (RT-qPCR) Sensitivity (%) | Discordance | Saliva specimen collection method | Ct value higher in saliva than respiratory sample |
|---------------------|------|-----------------------|---------------------|-------------------|------------------------|----------------------------------------|------------|----------------------------------|-----------------------------------------------|
| Trobajo-Sanmartín et al. [60] | Jan-21 | 636 | Unconfirmed symptomatic and asymptomatic patients | NPS | E gene | 171/327, 51.9% | three saliva only, 156 NPS only | Asked to pool saliva in their mouth first - asked to avoid eating/drinking at least 1h before collection | Yes |
| Ediz Tutuncu et al. [44] | Jan-21 | 53 | Asymptomatic and mildly symptomatic confirmed COVID-19 patients | NPS | RdRP gene | 48/53, 90.57% | five NPS only | Asked to spit between 3–4 ml of saliva – PBS was added | Mean difference not statistically significant |
| Goldfarb et al. [134] | Jan-21 | Confirmed COVID-19 patients | NPS | RdRP and E genes | 26/33, 79% | one saliva only, six NPS only | Asked to pool saliva and spit repeatedly a minimum of 5–10 ml | Yes |
| Hamilton et al. [76] | Jan-21 | 128 | Unconfirmed asymptomatic patients | 1. Undiluted NPS 2. Diluted NPS | ORF1ab, N and S genes | 11/19, 57.89% | 1. eight NPS only 2. three saliva only, five NPS only | Used OMNIgene sample collection tubes and buffer - asked to avoid eating/drinking/smoking at least 30 mins before collection | Yes |
| Babady et al. [63] | Jan-21 | | Unconfirmed symptomatic or close-contact patients | NPS | N gene (N1 and N2) | 1. 16/17, 94.12% 2. 29/35, 82.86% | 1. one saliva only, one NPS only 2. six saliva only, one OPS only | POPS. Stored at room temperature before processing | Mean difference not statistically significant |
| Echavarria et al. [135] | Feb-21 | 174 | Unconfirmed asymptomatic patients | NPS | E gene | 61/63, 98% | one saliva only, two NPS only | Self-collected without the addition of VTM | Yes |
| Teo et al. [43] | Feb-21 | 337 | Confirmed COVID-19 patients and both symptomatic and asymptomatic unconfirmed patients | NPS | 1. N1 and N2 genes 2. ORF1ab gene | 1. 209/337, 62% 2. 167/337, 49.6% | Not mentioned | Asked to tilt head back, clear both nose and throat and spit 2 ml into sterile container with 2 ml of RNA stabiliser fluid - asked to avoid eating/drinking/smoking at least 30 mins before collection | Not mentioned |
| Barat et al. [87] | Feb-21 | 459 | Unconfirmed symptomatic patients | NPS or midturbinate swab | N gene (N1 and N2) | 30/38, 81.5% | one saliva only, seven NPS/ midturbinate swab only | Asked to pool saliva in mouth for 30 s, and drool into sterile container until 3–5 ml was collected | Yes |
| Rodriguez Flores et al. [61] | Mar-21 | 30 | Confirmed COVID-19 patients | NPS | E and RdRP genes | 26/30, 88.2% | four NPS only | Supervised oral saliva collection stored in a cooler after collection | Yes |

Continued
| Study and reference | Date   | No. of paired samples | Patient information                                      | Respiratory sample | SARS-CoV-2 target genes | Saliva sample (RT-qPCR) Sensitivity (%) | Discordance | Saliva specimen collection method | Ct value higher in saliva than respiratory sample |
|---------------------|--------|-----------------------|----------------------------------------------------------|--------------------|-------------------------|----------------------------------------|-------------|---------------------------------|-----------------------------------------------|
| Borghi et al. [73]  | Mar-21 | 1. 192               | 1. Adult cohort                                          | NPS                | RdRP and N1 genes       | 1. 60/86, 69.76% 2. 9/12, 75% 3. 26/27, 96.3% | 1. one saliva only, 29 NPS only 2. 3 NPS only 3. six saliva only, one NPS only | A sterile dental cotton roll was used to collect saliva by holding in the mouth for 4 min total. Cotton roll was stored at room temperature until processing |
|                     |        | 2. 80                 | 2. Asymptomatic cohort                                   |                    |                         |                                        |             |                                 | No                                             |
|                     |        | 3. 109                | 3. Child cohort                                          |                    |                         |                                        |             |                                 |                                                |
|                     |        |                       |                                                          |                    |                         |                                        |             |                                 |                                                |
| Kernéis et al. [46] | Apr-21 | 1. 372               | Unconfirmed symptomatic and asymptomatic close contacts with three different saliva processing protocols 1. MDI-1 2. MDI-2 3. Roche | NPS                | 1. N, S and ORF1ab     | 1. 23% 2. 94% 3. 96%                    | 66 saliva only, five NPS only | Not mentioned | No |
|                     |        | 2. 1328               |                                                          |                    |                         |                                        |             |                                 |                                                |
|                     |        | 3. 1383               |                                                          |                    |                         |                                        |             |                                 |                                                |
| De Santi et al. [47]| Oct-21 | 1. 127               | 1. Hospitalised, symptomatic confirmed COVID-19          | NPS                | RdRP and N1 genes       | 82/87, 94.3%                           | nine saliva only (of which two were false positives), five NPS | Collect by passive drooling. Excluded if eating/drinking/oral hygiene/nasal sprays were consumed 30 min before collection | Mean difference not statistically significant |
|                     |        | 2. 181                | 2. Unconfirmed asymptomatic                              |                    |                         |                                        |             |                                 |                                                |
| LeGoff et al. [48]  | Oct-21 | 1718                 | Unconfirmed patients, one third of which were symptomatic | NPS                | ORF1ab, N and S genes   | 93%                                    | Not mentioned; although saliva detected more positives, 153, compared to only 110 for NPS, indicating 43 were saliva only | Self-collected saliva, patients were asked to swish around saliva in their mouths for 30 s before spitting - asked to avoid eating/drinking/smoking at least 30 mins before collection | Not mentioned |
|                     |        |                       |                                                          |                    |                         |                                        |             |                                 |                                                |
The transportation and storage of the saliva before processing also varied, with some adding VTM [15, 19, 35, 40, 56], UTM (universal transport medium) [59], amies medium [52], phosphate buffer saline (PBS) [55, 82] and/or storing at 4 °C/freezing [41, 45, 54, 55, 83–85] until processing and others using crude saliva and/or stored at room temperature [38, 39, 63, 86]. The studies that added VTM, UTM, amies medium or PBS to saliva samples had sensitivities that ranged from 77 % [55] to 91.7 % [15]. The studies that used VTM [15, 35, 40, 56], which is the transport medium used for NPS specimens, tended to have higher sensitivities.

![Fig. 1. Overview of saliva and NPS specimen collection and processing for COVID-19 diagnosis including potential pitfalls in sample collection and processing (red) that could lead to variability in the specimen's sensitivity.](image)

![Fig. 2. Source and location of posterior oropharyngeal saliva and oral cavity saliva. Taken from [105] with permission.](image)
Table 2. Strengths and weakness of NPS and saliva specimens

| Specimen | Strengths | Limitations |
|----------|-----------|-------------|
| NPS      | - Already established as the specimen of choice for the diagnosis of many viral respiratory infections [4, 5]  
- Likely to be less variation in the sensitivity of the specimen if food/drink etc. is consumed before sample is taken  
- Antigen tests are established for using NPS as their input | - Uncomfortable and invasive specimen to collect  
- Not suitable for children  
- Requires trained HCWs in order for the sample to be collected  
- Puts HCWs at risk of nosocomial infection  
- Incorrect swabbing due to poor technique from administrator or resistance from the patient can impact sensitivity  
- Not suitable for mass-testing/surveillance due to logistics and repeated sampling can cause adverse effects to the patient [13] |
| Saliva   | - Less invasive specimen to collect and therefore patients are more likely to get tested and give repeated samples  
- Can be self-administered from home, so no trained HCWs or test sites are required  
- Suitable for COVID-19 mass testing/surveillance | - No established collection, transport and processing protocol  
- Time of day of sampling as well as food/drink/oral hygiene/smoking can impact the specimen's sensitivity  
- Antigen tests are not established for using saliva as their input |

than those that used other transport media [52, 55, 59, 82], although this may be due to other parameters of these studies such as that they [15, 35, 40, 56] all used POPS, which as aforementioned may potentially have a higher viral load compared to oral saliva, which was used for the other studies. Some studies have noted that crude saliva can be difficult and time-consuming to process due to its viscosity, sometimes congealing after collection and thus recommend the addition of diluents such as VTM at collection or proteases (e.g. mucolyse or proteinase K) before processing to ensure saliva is amenable for pipetting and further downstream processing [59, 70, 76, 86, 87]. Although it is not noted in the studies that used POPS examined for this review, this may be a particular issue with this specimen type over oral saliva as the potential mixing with sputum during throat clearing to obtain the specimen could increase its viscosity. This is especially an issue when trying to automate the diagnostic protocol to increase testing speed and capacity, where one study that developed a robotic RNA extraction step noted significant issues in using saliva specimens for this due to the inherent variable nature and viscosity of saliva specimens [76]. In many studies, and indeed in most saliva diagnostic tests that have been granted EUAs by the US FDA, stabilisers and preservatives are added to saliva specimens in order to minimise RNA degradation and thus maximise SARS-CoV-2 detection [16]. However, others have concerns that the addition of VTM/other transport media and stabilisers/preservatives may dilute the sample and/or reduce its sensitivity [25, 54, 86]. A recent study has found that SARS-CoV-2 RNA remains stable and detectable without a statistically significant raise in Ct values in saliva specimens that have both not had preservatives/stabilisers added nor have been stored at refrigeration/freezing temperatures, negating the need for these processes in the diagnostic protocol, particularly if additives may interfere with/reduce diagnostic sensitivity [16]. This further highlights the applicability of saliva specimens for diagnosis particularly in resource-limiting regions where preservatives/stabilisers, as well as VTM which is required for NPS specimen collection, and/or refrigeration/freezing facilities may be limited.

Of the studies that mentioned how they stored their saliva samples, those that stored theirs at 4°C [41, 45, 54, 83] had sensitivities ranging from 78.6% [45] to 92% [41], while those that mentioned storing theirs at −80°C [55, 84, 85] had sensitivities ranging from 77% [55] to 94.5% [84] and those that mentioned storing theirs at room temperature [38, 39, 63, 73, 86] had sensitivities ranging from 69.76% [73] to 94.12% [63]. Whilst freeze-thawing can reduce the concentration/integrity of RNA in samples [85, 88], a high sensitivity of 94.5% of −80°C stored saliva samples were obtained in Vaz et al. [84]. Additionally, Ott et al. did not notice a statistically significant rise in Ct values of saliva samples that were stored at room temperature over a number of days [16] and thus it remains unclear what is the optimum storage conditions of saliva as clearly high sensitivities can be achieved with storage at 4°C, freezing (−20°C or −80°C) and room temperature. The US Centres for Disease Control and Prevention (CDC) guidelines advice storing NPS specimens at 2–8°C for up 72 h before processing and if processing is delayed beyond that, to store the samples at −70°C or below [89].

Thus, there is clearly great diversity in the saliva collection, transport and storage protocols being employed which could explain the discrepancies in saliva sensitivity between studies. Comparatively, there are fewer potential variables in collecting NPS due to a standard protocol being in place where all NPS are placed only in VTM after collection (Fig. 1), typically refrigerated before processing and patients consuming food/beverages etc. does not appear to have any influence on sensitivity. However, reduced sensitivity can be seen in NPS specimens if there is poor technique used by the administrator (i.e. if the swab does not reach all the way to the nasopharynx or has limited contact time at the nasopharynx thus reducing the chances of collecting the virus) [90], which may occur for example if the swab is self-administered such as in [91, 92], or if there is patient resistance due to uncomfortable and invasive nature of NPS collection (Fig. 1, Table 2). Czumbel et al. remark that in order for saliva data to be reliable and comparable, there must be standardisation of an optimal collection and processing protocol [25]. Otherwise, as Hung and colleagues observe, discrepancies between results may be as a result of poor specimen collection technique, such as in one study where saliva samples were taken directly from the opening of the salivary glands and thus only correctly identified four out of 31 confirmed COVID-19 cases [57, 79].
Sensitivity of saliva versus nasopharyngeal swabs

Specimen sensitivity for COVID-19 diagnosis, especially in asymptomatic/mild cases, is vital for disease control as the consequences of false negative results can lead to otherwise preventable outbreaks [93]. Importantly, no diagnostic test has both 100% sensitivity and specificity, with NPS only having a detection rate of around 63% [94, 95], with an estimated false negative rate ranging from 20–38% after symptom onset, which are increasingly more likely in the days before symptoms begin and during the convalescent phase [96]. As aforementioned, there is great heterogeneity in the saliva collection, transport and storage protocols used in studies examining saliva sensitivity. There is no difference in the processing protocols used for saliva specimens which can influence sensitivity of the assay. This is demonstrated by Kernéis et al., where they experimented with three different protocols for saliva processing and saw drastic changes in sensitivity [46]. The MGI-1 protocol, which was designed for NPS specimens, only had a sensitivity of 23% with saliva, however, when it was adjusted by changing the lysis buffer to better suit saliva specimens (MGI-2 protocol), the sensitivity increased to 94%, dramatically highlighting the importance and standardisation of an accurate protocol and how different protocols can influence saliva sensitivity.

In comparing saliva to NPS, most studies reported discordance where neither specimen detected all positive cases with saliva samples detecting SARS-CoV-2 RNA where NPS samples were negative and vice versa (Table 1). Jamal et al. note that in studies that involving confirmed COVID-19 patients diagnosed using NPS, there may be a bias towards subsequent NPS over other specimens being positive [55]. Furthermore, Czumbel et al. point out that this discordance may not be because one specimen is ‘better’ than the other, but could be as a result of the varying sites of SARS-CoV-2 replication during the course of infection, where it is thought to begin in the nasal mucosa, or potentially in the oral mucosa [34], and subsequently disseminate down the respiratory tract, therefore specimen sensitivity may depend on the spatiality and temporality of SARS-CoV-2 replication during the course of infection [25, 97]. Borghi et al. found that SARS-CoV-2 was detectable in two saliva samples 48 h before it was detected in an NPS from the same individual indicating viral replication may begin in the oropharynx [73]. A similar result was seen in Savela et al., who found that although NPS had the higher viral loads overall, saliva was able to detect SARS-CoV-2 up to 4.5 days before NPS [92]. However, a limitation of this study was the small sample size (seven in total) and that the NPS were self-administered which could diminish sensitivity thus further work with a larger sample size is needed to confirm this. Such results also may explain the variation in viral loads between the two specimens, where some studies reported that saliva specimens had a higher cycle threshold (Ct) value signifying a lower viral load compared to NPS specimens whereas others reported the opposite (Table 1). De Santi et al. found that in a hospitalised symptomatic patient cohort, NPS and saliva specimen sensitivity decreased at a consistently similar rate as time progressed over a course of greater than 7 days from the patients’ initial positive diagnostic result [47]. Whereas Wyllie et al. found that more saliva samples remained positive 10 days after initial diagnosis than their corresponding NPS samples [91]. Nonetheless, from these studies it would appear that the sensitivity of saliva and NPS decrease at least at a similar rate. To et al. found viral load to be highest in saliva earlier in infection and found it declined over the course of disease [15] similar to Zhu et al. who found viral load in saliva to peak 1 week after symptom onset followed by a steady decline, but in 8/20 patients it remained detectable greater than 14 days from symptom onset which interestingly, was not correlated with disease severity [98]. Another study found the positive percentage agreement (PPA) was highest between saliva and NPS when saliva was collected within 9 days of symptom presentation, 65.6–93.5%, compared to saliva collected 10 days after symptom onset, 22.2–66.7%, and saliva obtained from asymptomatic patients, 40–66.7% [82]. Similarly Wong et al. reported a PPA of 96.6% when saliva was collected within 7 days of symptom onset and discordance was more likely to occur when saliva was collected after 7 days [19].

It has been noted that positive NPS samples with a corresponding negative saliva sample had high Ct values thus indicating that the discordant saliva sample may be as a result of low viral loads which are below the detection limit of RT-qPCR [65, 86]. For example, De Santi et al. recorded nine saliva only positives and five NPS only positives [47]. This study used the RNA extraction-free protocol for saliva processing, SalivaDirect, developed by Vogels et al. [24] but were unique among the studies we looked at in that they verified their discordant results again, this time using the TaqPath COVID-19 CE-IVD RT-PCR kit and found that 7/9 of the discordant saliva results were indeed true positives that had not been detected in the corresponding NPS samples, with only two being false positives but these had had Ct values >35 in the SalivaDirect protocol. The corresponding five false negative saliva samples remained undetected were likely due to low viral loads in saliva as the corresponding NPS samples had Ct values >30.

In studies that compared saliva sensitivity to NPS in mild/asymptomatic patients, two studies in particular found lower saliva sensitivities at 53% [49] and 68.6% [50]. This lower sensitivity may be as a result of poor specimen collection as both studies poorly described saliva collection protocol. The former pooled saliva specimens and the latter used a novel saliva collection kit containing viricidal fluid and preservatives which may have affected sensitivity of detection. Another study with a diverse sample cohort of both symptomatic and asymptomatic individuals found that saliva also had much lower sensitivity compared to NPS at 51.9% [60]. However, when this study only included saliva positive results with a Ct value ≤30, the sensitivity of saliva specimens increased to 91.6% indicating low viral load may be a possible reason for this discordance between saliva and NPS specimens [60]. Conversely, other studies found much higher saliva sensitivity at 93% [39], 92% [41], and 91.37% [99] in mild/asymptomatic patients. Wyllie et al. screened 495 asymptomatic HCWs and found 13 positive saliva samples of which only two had a corresponding positive NPS indicating saliva is more sensitive for detecting asymptomatic infection [91]. However, a
limitation of this study is that the NPS were self-administered and thus may be more likely to be inaccurate due to the technical challenge and discomfort of a self-administered NPS.

Thus, it is difficult to directly compare saliva and NPS sensitivities between current studies due to their heterogeneity but from the research so far it would appear that saliva sensitivity is at least comparable to NPS, especially if saliva specimen collection is supervised [100]. Further research to conclude what conditions i.e. collection and processing protocol, time from symptom onset etc., optimise saliva specimen sensitivity is still required to fully determine the optimal saliva collection and processing protocol as it is clear that under certain conditions saliva is less reliable and in others it is equal to/more reliable than NPS.

**Saliva as a diagnostic specimen for mass-testing and COVID-19 surveillance**

Mass testing has been advocated as a key for controlling the pandemic. As the easing of restrictions corresponds with a rise in cases, mass testing and surveillance is crucial for breaking this cycle as well as providing countries with opportunities to catch new variants before they become widespread. With NPS currently being unable to keep up with testing demands, saliva offers a number of advantages to facilitating mass testing. Firstly, it is cost-effective, with one study estimating processing 100 saliva specimens costs $8.24 compared to $104.87 for 100 NPS [19]. Secondly, it alleviates specimen collection ‘bottlenecks’ due to supply shortages and wait-times as it has the potential to be self-administered from home. Thirdly, the non-invasive nature of saliva collection means individuals are more likely to give repeated samples for surveillance and monitoring. Additionally, multiple saliva samples, for example from the same household, could be pooled together which could further relieve strains on testing facilities allowing 5–10 samples to be processed as one [76, 87, 101, 102]. Although, pooling of saliva samples was shown in these studies to slightly reduce detection sensitivity. Ultimately, whilst saliva specimens can relieve some of the pressures seen with NPS, the diagnosis step, RT-qPCR, still takes the same amount of time, labour and resources [49]. Whilst in theory, an RT-qPCR result should be available in a number of hours from sample collection, in reality, due to testing demand, resource availability etc. the lag time between testing and receiving diagnostic results can be up to 3 days with RT-qPCR-based tests [103] which may result should be available in a number of hours from sample collection, in reality, due to testing demand, resource availability etc. the lag time between testing and receiving diagnostic results can be up to 3 days with RT-qPCR-based tests [103] which may contribute to viral spread particularly if individuals are asymptomatic or are not self-isolating.

This has led to the development of a number of point-of-care tests (POCT) using saliva as the diagnostic specimen, such as reverse-transcription loop-mediated isothermal amplification (RT-LAMP) which unlike RT-qPCR does not require thermal cycling for nucleic acid amplification, and often excludes an RNA extraction step or uses a simpler RNA extraction method such as treatment with a protease followed by heat [104], allowing for rapid diagnosis in hospitals/clinical settings as well as in resource-limited settings as the only equipment required is a heat-block [104–107]. However, Taki et al. found that without an RNA extraction step, saliva RT-LAMP only had a sensitivity of 47% but with an RNA extraction step it had a sensitivity of 100% indicating this step is vital for RT-LAMP sensitivity [108]. Other POCTs, such as Cepheid’s Xpert Xpress SARS-CoV-2 assay, which has been granted an EUA by the US FDA [109], allows for rapid results within 35–45 min without any extensive sample processing steps and has been used with saliva specimens for SARS-CoV-2 diagnosis in some studies with very high sensitivity rates when compared to NPS specimens with RT-qPCR at 100% [110], 95.92% [64] and 89.7% [56]. However, as Landry et al. note, there are limitations in the applicability of the Xpert Xpress SARS-CoV-2 assay to mass-testing due to the limited availability of GeneXpert systems and its unsuitability to process large numbers of samples [70].

The development of point-of-need tests (PONT) such as lateral flow, or rapid antigen, assays that detect SARS-CoV-2 antigens like spike protein [111] or nucleocapsid protein [112] have also been developed which allow for rapid, onsite diagnosis within 15–30 min without any laboratory equipment and thus could be performed in schools, businesses, concerts etc. [105]. The majority of these rapid antigen detection (RAD) tests have been designed with NPS as their input which of course carries the same disadvantages as with it being the specimen for RT-qPCR. Therefore, a number of studies have examined various RAD tests with saliva specimens as their input [82, 112–115]. However, all have found saliva in conjunction with the RAD test to be less sensitive than both NPS as the input for the RAD test and RT-qPCR. It is important to consider that these RAD tests are often validated and designed for the use of NPS and therefore might by biased towards NPS over saliva or there may be inhibitory factors present in saliva which may explain the reduced sensitivity seen when saliva is the input specimen. Additionally, there is a general consensus that RAD tests are typically less sensitive than RT-qPCR, even when NPS is used as the input specimen [116, 117]. However, this should not be the primary focus of RAD tests as the purpose of their design is to have a rapid and accessible means of testing that would allow for the detection of otherwise undetected cases in social settings that could result in a preventable outbreak. Therefore, it is argued that the frequency that these PONTs are employed combined with their rapidity is more important than their sensitivity for COVID-19 surveillance [118]. That being said, a recent evaluation of a number of RAD tests by Public Health England found that the promising Innova lateral flow test, which uses a nasal swab as the specimen, successfully detected 79.2% of COVID-19 cases when carried out by trained laboratory scientists but only successfully detected 58% of COVID-19 cases when carried out by self-trained lay people which raises concerns that if the specificity of these tests is dependent on the level of training/expertise of the individual conducting the test it could result in false negative results when these tests are widely implemented to the public outside of clinical trials [119]. Whilst both POCT and PONT with saliva as the diagnostic specimen would allow for diagnosis in resource-limited regions/countries as well as holding promise for a return to
normality allowing for rapid screening in social settings, further research and optimisation of these tests is still required to evaluate and optimise their sensitivity in order to maximise their COVID-19 mass-screening potential [82].

It is also important to mention that in addition to saliva being an alternative diagnostic specimen to NPS, it has been demonstrated to substitute as a much less invasive and more easily obtainable specimen to serum samples to measure seropositivity following COVID-19 infection, with comparable levels of antibodies, in particular IgG, between paired saliva and serum samples [120, 121]. Thus, the easily obtainable saliva specimen could potentially be applied for mass ‘séro-surveillance’ in addition to mass-testing to measure the levels of active infection and immunity, both natural and vaccine acquired, in the community [121, 122]. As the end of the COVID-19 pandemic is far from being insight, an easily testable sample to measure immunity might be of particular importance in the future as the longevity of vaccine-acquired immunity to COVID-19 infection is unknown.

**Limitations**

The use of saliva as a specimen for COVID-19 diagnosis is not without its limitations and as aforementioned, a major concern is its sensitivity which has been discussed above. However, other limitations of using saliva as a specimen include that several studies reported that a number of saliva specimens were of insufficient volume/quality for processing [41, 42, 53, 67, 76, 85, 86, 123]. Thus, as Leung et al. note, step-by-step instructions are vital for collection of saliva samples of sufficient quality and quantity [40]. However, Fernández-González et al. compared self-collected saliva with only written instructions provided verses trained HCW-supervised collection of saliva specimens and found that when supervised, saliva specimens had 86% sensitivity compared to NPS whereas self-collected specimens only had 66.7% sensitivity, indicating that perhaps supervised collection is necessary to maximise saliva specimen quality which may limit the implementation of ‘from home’ self-collected saliva samples [100]. Interestingly, as Sagredo-Olivares et al. note, some studies reported employing telemedicine sessions with trained HCWs to ensure saliva specimen collection is done correctly and sufficiently from home [45, 124–126], which may offer a number of advantages to limit nosocomial infections and testing wait-time bottlenecks allowing at-home specimen collection whilst ensuring saliva specimen integrity [127]. Two studies also noted that whilst saliva sample collection has the potential to be self-administered by the patient in the absence of a trained HCW, it is important that the tube is decontaminated after as it has been noted that patients can spill the sample onto the outside of the tube, which if it contains infectious particles could put individuals processing the sample at risk of infection [47, 61]. Finally, saliva is not a suitable specimen for intubated patients as well as for those who may have difficulty producing saliva due to co-morbidities and/or medications [49, 54, 59].

As previously outlined, the variation in specimen collection and processing protocols between studies, with variations even within some studies [58], is a major limitation of the literature thus far and possibly explains the discordance in results seen between studies. It’s difficult to compare the sensitivities/accuracy between studies if the experimental parameters such as specimen collection protocol, transport and storage, PCR amplification targets, patients’ status etc. are not the same. In the majority, study design was also poor with small sample sizes, lack of blinding and of control-group samples with many studies only containing confirmed COVID-19 patients [128]. In order for fair comparisons to be made, there needs to be diversity in the sample cohort, particularly containing mild/asymptomatic patients who make up 80% of COVID-19 cases and are likely to have a lower viral load [129, 130]. The implementation of a standard processing protocol, such as the SalivaDirect protocol, which accommodates the use of different kits/reagents and eliminates the RNA extraction step, could reduce the variation in sensitivities that occur due to differences in sample processing [24]. This protocol has been verified by other research groups, where Rodríguez Flores et al. found the SalivaDirect protocol to have 88% sensitivity compared to NPS [61] and De Santi et al. found it to have 94.3% sensitivity compared with NPS [47]. Interestingly, the former study also used the SalivaDirect protocol with NPS and found this to be slightly more sensitive, with 93.7% sensitivity, than when saliva was used as the input for the SalivaDirect protocol which would indicate that NPS is the slightly more sensitive specimen due to higher viral load in this sample type, indicated by lower Ct values [61].

Also, a number of studies are not peer-reviewed [24, 38, 46, 49, 54, 58, 65, 76, 92, 99] and therefore these results should be interpreted cautiously and more rigorously conducted studies should be carried out before definitive conclusions can be made [10, 79].

**Conclusion**

It is going to be a significant amount of time before enough of the world’s population are vaccinated and a sustained reduction of COVID-19 incidence will be seen. Therefore, identification of positive cases and the subsequent isolation of these individuals remains to be the most effective control mechanism of preventing COVID-19 spread thus far. Thus, a test that is accurate, convenient, cost-effective, is not dependent on specific supplies such as swabs, has patient acceptability and is suitable for mass-testing is required. NPS have failed to satisfy these requirements and saliva has emerged as a promising replacement and/or alternative specimen with a number of advantages. Whilst concerns over sensitivity of saliva specimens compared to NPS have been raised, it is clear that under the right collection, transport/storage and processing conditions saliva can be as sensitive and in some studies more sensitive than NPS specimens for COVID-19 diagnosis. Further research into the development of an optimum collection and processing protocol could attenuate the variation in sensitivities seen between studies. Nonetheless, a potential slight reduction in sensitivity compared to the reference standard might still be acceptable in specific testing environments...
such as mass-testing/surveillance and resource-limited settings, especially when considering the numerous advantages of saliva specimens [10].

Funding information
The authors received no specific grant from any funding agency.

Acknowledgements
The Authors would like to thank Professor John Morrissey and Dr Niall O’Leary for their constructive criticism and encouragement. Fig. 1 in this paper was created using www.BioRender.com; and Fig. 2 was adapted with permission from Professor Lorenzo Azzi (University of Insubria, Italy).

Author contributions
L.M.P., wrote the manuscript, J.M.S., conceived, reviewed and edited the manuscript.

Conflicts of interest
The authors declare that there are no conflicts of interest.

References
1. Centers for Disease Control and Prevention. Emerging SARS-CoV-2 Variants; 2021. https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html
2. Our World in Data. Coronavirus (COVID-19) Vaccinations; 2021. https://ourworldindata.org/covid-vaccinations
3. World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases; 2021. https://www.who.int/publications/i/item/10665-331501
4. Li L, Chen Q-Y, Li Y-Y, Wang Y-F, Yang Z-F, et al. Comparison among nasopharyngeal swab, nasal wash, and oropharyngeal swab for respiratory virus detection in adults with acute pharyngitis. BMC Infect Dis 2013;13:281.
5. Lieberman D, Lieberman D, Shimon A, Keren-Naus A, Steinberg R, et al. Identification of respiratory viruses in adults: nasopharyngeal versus oropharyngeal sampling. J Clin Microbiol 2009;47:3439–3443.
6. World Health Organization. Laboratory testing strategy recommendations for COVID-19; interim guidance, 21 March 2020. Geneva: World Health Organization; 2020 2020. Contract No.: WHO/2019-nCoV/lab_testing/-/ 2020. https://apps.who.int/iris/handle/10665/331509 [accessed 16 December 2021].
7. Centers for Disease Control and Prevention. Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic; 2021. https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html
8. Kaplan EH, Forman HP. Logistics of Aggressive Community Screening for Coronavirus 2019. JAMA Health Forum 2020;1:e200565.
9. Fraize BW, Rodriguez-Hoces de la Guardia A, Alter H, Chen CG, Fuentes EL, et al. Accuracy and discomfort of different types of intranasal specimen collection methods for molecular influenza testing in emergency department patients. Ann Emerg Med 2018;71:509–517.
10. Comber L, Walsh KA, Jordan K, O’Brien KK, Clyne B, et al. Alternative clinical specimens for the detection of SARS-CoV-2: A rapid review. Rev Med Virol 2021;31:e2185.
11. Sri Santosh T, Parmar R, Anand H, Srikanth K, Saritha M. A review of salivary diagnostics and its potential implication in detection of covid-19. Cureus 2020;12:e7708.
12. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet 2020;395:514–523.
13. Gupta K, Bellino PM, Charness ME. Adverse effects of nasopharyngeal swabs: Three-dimensional printed versus commercial swabs. Infect Control Hosp Epidemiol 2021;42:641–642.
14. Kim Y-G, Yun SG, Kim MY, Park K, Cho CH, et al. Comparison between Saliva and Nasopharyngeal Swab Specimens for Detection of Respiratory Viruses by Multiplex Reverse Transcription-PCR. J Clin Microbiol 2017;55:226–233.
15. To KK-W, Tsang OT-Y, Yip CC-Y, Chan K-H, Wu T-C, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis 2020;71:841–843.
16. Ott IM, Strine MS, Watkins AE, Boot M, Kalinich CC, et al. Stability of SARS-CoV-2 RNA in Nonsupplemented Saliva. Emerg Infect Dis 2021;27:1146–1150.
17. World Health Organization. Diagnostic testing for SARS-CoV-2; 2021. https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2
18. The Government of the Hong Kong Special Administrative Region. HA enhanced laboratory surveillance programme extends to outpatients with mild symptoms; 2021. https://www.info.gov.hk/gia/gia/general/20200228/P2020021800437.htm2020
19. Wong SCY, Tse H, Siu HK, Kwong TS, Chu MY, et al. Oropharyngeal Saliva for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71:2939–2946.
20. University of Illinois. Shield Illinois Saliva Test; 2021. https://www.uillinois.edu/shield2020
21. University of South Carolina. Saliva Assay Free Expedited (SAFE); 2021. https://usc.edu/study/colleges_schools/pharmacy/research_and_practice/research_areas/covid19/salivatest/index.php2020
22. Minnesota Department of Health. COVID-19 Test at Home; 2021. https://www.health.state.mn.us/diseases/coronavirus/test-sites/athome.html
23. U.S. Food and Drug Administration. ACCELERATED EMERGENCY USE AUTHORIZATION (EUA) SUMMARY SARS-CoV-2 ASSAY (Rutgers Clinical Genomics Laboratory); 2021. https://www.fda.gov/media/136875/download
24. Vogels CBF, Watkins AE, Harden CA, Brackney DE, Shafer J, et al. SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity. Med (N Y) 2021;2:263–280.
25. Czumbel LM, Kiss S, Farkas N, Mandel I, Hegyi A, et al. Saliva as A Candidate for COVID-19 Diagnostic Testing: A Meta-Analysis. Front Med (Lausanne) 2020;7:465.
26. Xu J, Li Y, Gan F, Du Y, Yao Y. Salivary Glands: Potential Reservoirs for COVID-19 Asymptomatic Infection. J Dent Res 2020;99:988.
27. Xu H, Zhong L, Deng J, Peng J, Dan H, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 2020;12.
28. Pascolo L, Zupin L, Melato M, Tricarico PM, Crovella S. TMPRSS2 and ACE2 Coexpression in SARS-CoV-2 Salivary Glands Infection. J Dent Res 2020;99:1120–1121.
29. Song J, Li Y, Huang X, Chen Z, Li Y, et al. Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS-CoV-2. J Med Virol 2020;92:2556–2566.
30. Hamming I, Timens W, Bultjens MLC, Lely AT, Navis GJ, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631–637.

31. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;181:271–280.

32. Zang R, Gomez Castro MF, McCune BT, Zeng Q, Rothlauf PW, et al. TMPRSS2 and TMPRSS5 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol 2020;5:47.

33. Liu L, Wei Q, Alvarez X, Wang H, Du Y, et al. Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus macaques. J Virol 2011;85:4025–4030.

34. Huang N, Pérez P, Kato T, Mikami Y, Okuda K, et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat Med 2021;27:892–903.

35. To KK-W, Tsang OT-Y, Leung WS, Tam AR, Wu T-C, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020;20:565–574.

36. Gupta S, Mohindra R, Chauhan PK, Singla V, Goyal K, et al. SARS-CoV-2 detection in gingival crevicular fluid. J Dent Res 2021;100:187–193.

37. Dawes C, Wong DTW. Role of saliva and salivary diagnostics in the advancement of oral health. J Dent Res 2019;98:133–141.

38. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, et al. Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. N Engl J Med 2020;383:1283–1286.

39. Rao M, Rashid FA, Sabri F, Jamil NN, Zain R, et al. Comparing nasopharyngeal swab and early morning saliva for the identification of SARS-cov-2. Clin Infect Dis 2020;72:e352–e356.

40. Leung E-M, Chow V-Y, Lee M-P, Lai R-M. Deep throat saliva as an alternative diagnostic specimen type for the detection of SARS-CoV-2. J Med Virol 2021;93:533–536.

41. Yokota I, Shane PY, Okada K, Unoki Y, Yang Y, et al. Mass screening of asymptomatic persons for SARS-CoV-2 using saliva. Clin Infect Dis 2020;73:e559–e565.

42. Procop GW, Shrestha NK, Vogel S, Van Sickle K, Harrington S, et al. A Direct Comparison of Enhanced Saliva to Nasopharyngeal Swab for the Detection of SARS-CoV-2 in Symptomatic Patients. J Clin Microbiol 2020;58:e00776-20.

43. Teo AKJ, Choudhury Y, Tan IB, Cher CY, Chew SH, et al. Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection. Sci Rep 2021;11:3134.

44. Tutuncu E, Ozgur D, Karamese M. Saliva Samples for Detection of SARS-CoV-2 in Mildly Symptomatic and Asymptomatic Patients. SSRN Journal 2020;9:2932–297.

45. Braz-Silva PH, Mamana AC, Romano CM, Felix AC, de Paula AV, et al. Performance of at-home self-collected saliva and nasopharyngeal swabs in the surveillance of COVID-19. J Oral Microbiol 2020;13:1858002.

46. Kernéis S, Elie C, Fourgeaud J, Choupeaux L, Delarue SM, et al. Accuracy of antigen and nucleic acid amplification testing on saliva and nasopharyngeal samples for detection of SARS-cov-2 in ambulatory care. medRxiv 2021:2021.

47. De Santi C, Jacob B, Kroich P, Doyle S, Ward R, et al. Concordance between PCR-based extraction-free saliva and nasopharyngeal swabs for SARS-CoV-2 testing. HRB Open Res 2021;4:45.

48. LeGoff J, Kernéis S, Elie C, Mercier-Delarue S, Gastiñ N, et al. Evaluation of a saliva molecular point of care for the detection of SARS-CoV-2 in ambulatory care. Sci Rep 2021;11:21126.

49. Nacher M, Mergues-Fabre M, Blanchet D, Benois O, Pozl T, et al. Prospective comparison of saliva and nasopharyngeal swab sampling for mass screening for COVID-19. Epidemiology 2020;2020:2020.

50. Caulley L, Corsten M, Eapen L, Whelan J, Angel JB, et al. Salivary Detection of COVID-19. Ann Intern Med 2021;174:131–133.

51. Miguez N, Mengelle C, Diméglio C, Didier A, Alvarez M, et al. Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers. J Clin Virol 2020;130:104580.

52. Williams E, Bond K, Zhang B, Putland M, Williamson DA, et al. Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2. J Clin Microbiol 2020;58:e00776-20.

53. Van Vinh Chau N, Lam VT, Dung NT, Yen LM, Minh NNN, et al. The Natural History and Transmission Potential of Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clin Infect Dis 2020;71:2679–2687.

54. Griesemer SB, Van Slyke G, Ehrbar D, Strie K, Yildirim T, et al. Evaluation of Specimen Types and Saliva Stabilization Solutions for SARS-CoV-2 Testing. J Clin Microbiol 2021;59:2020.

55. Jamal AJ, Mozafarishahin M, Coomes E, Powis J, Liu AX, et al. Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infectious Diseases (except HIV/AIDS) 2020.

56. Chen JH-K, Yip CCY, Poon RW-S, Chan K-H, Cheng VC-C, et al. Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2. Emerg Microbes Infect 2020;9:1356–1359.

57. Chen L, Zhao J, Peng J, Li X, Deng X, et al. Detection of SARS-CoV-2 in saliva and characterization of oral symptoms in COVID-19 patients. Cell Prolif 2020;53:e12923.

58. Becker D, Sandoval E, Amin D, De Hoff P, Diets A, et al. Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection in the community setting. medRxiv. 2020;2020. DOI: 10.1101/2020.05.11.20092338 [preprint].

59. Berenger BM, Conly JM, Fonseca K, Hu J, Louie T, et al. Saliva collected in universal transport media is an effective, simple and high-volume amenable method to detect SARS-CoV-2. Clin Microbiol Infect 2021;27:656–657.

60. Trobajo-Sanmartin C, Adelantado M, Navascués A, Guembe MJ, Rodrigo-Rincón I, et al. Self-Collection of Saliva Specimens as a Suitable Alternative to Nasopharyngeal Swabs for the Diagnosis of SARS-CoV-2 by RT-qPCR. JCM 2021;10:299.

61. Rodríguez-Flores SN, Rodríguez-Martínez LM, Reyes-Berrones BL, Fernández-Santos NA, Sierra-Moncada EJ, et al. Comparison between a standard and SalivaDirect RNA extraction protocol for molecular diagnosis of SARS-CoV-2 using nasopharyngeal swab and saliva clinical samples. Front Bioeng Biotechnol 2021;9:638902.

62. Fan J, Yu F, Wang X, Zou Q, Lou B, et al. Hock-A-logie saliva as A diagnostic specimen for SARS-CoV-2 by a PCR-based assay: A diagnostic validity study. Clin Chim Acta 2020;511:177–180.

63. Babady NE, McMillen T, Jani K, Viale A, Robilotti EV, et al. Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Real-Time RT-PCR Tests on Oral Rinses and Saliva Samples. J Mol Diagn 2021;23:3–9.

64. McCormick-Baw C, Morgan K, Gaffney D, Cazes Y, Jaworski K, et al. Saliva as an alternate specimen source for detection of SARS-CoV-2 in Symptomatic Patients Using Cepheid Xpert Xpress SARS-CoV-2. J Clin Microbiol 2020;58:e01109- 20.

65. Rodríguez-Flores SN, Rodríguez-Martínez LM, Reyes-Berrones BL, Fernández-Santos NA, Sierra-Moncada EJ, et al. Comparison between a standard and SalivaDirect RNA extraction protocol for molecular diagnosis of SARS-CoV-2 using nasopharyngeal swab and saliva clinical samples. Front Bioeng Biotechnol 2021;9:638902.
caution in mild outpatient cohorts with low prevalence. Clin Microbiol Infect 2020;26:1711–1713.

68. Iwasaki S, Fujisawa S, Nakakubo S, Kamada K, Yamashita Y, et al. Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva. J Infect 2020;81:e145–e147.

69. Azzi L, Carcano G, Gianfagna F, Grossi P, Gasperina DD, et al. Saliva is a reliable tool to detect SARS-cov-2. J Infect 2020;81:e45–e50.

70. Landry ML, Criscuolo J, Peaper DR. Challenges in use of saliva for detection of SARS CoV-2 RNA in symptomatic outpatients. J Clin Virol 2020;130:104567.

71. Senok A, Alsuwaidi H, Atrah Y, Al Ayedi O, Al Zahid J, et al. Saliva as an Alternative Specimen for Molecular COVID-19 Testing in Community Settings and Population-Based Screening. Infect Drug Resist 2020;13:3393–3399.

72. Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020;9:386–389.

73. Borghi E, Massa V, Carmagnola D, Dellavia C, Parodi C, et al. Saliva sampling for chasing SARS-CoV-2: A Game-changing strategy. Pharmacolet 2021;165:109380.

74. Chen Q, Zheng Z, Zhang C, Zhang X, Wu H, et al. Clinical characteristics of 145 patients with coronavirus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. Infect 2020;48:543–551.

75. Fernandes LL, Pacheco VB, Borges L, Athwal HK, Paula Eduardo F, et al. Saliva in the diagnosis of COVID-19 A reiew and new research directions. J Dent Res 2020;99:1435–1443.

76. Hamilton JR, Stahl EC, Tsuchida CA, Lin-Shiao E, Tsui CK, et al. Robotic RNA extraction for SARS-CoV-2 surveillance using saliva samples. medRxiv 2021:10.1101.202119151.

77. Chojnowska S, Baran T, Wilinska I, Sienicka P, Cabaj-Wiater I, et al. Human saliva as a diagnostic material. Adv Med Sci 2018;63:185–191.

78. Tajima Y, Suda Y, Yano K. A case report of SARS-cov-2 confirmed in saliva samples up to 37 days after onset: proposal of saliva specimen for COVID-19 diagnosis and virus monitoring. J Infect Chemother 2020;26:1086–1089.

79. Hung K-F, Sun Y-C, Chen B-H, Lo J-F, Cheng C-M, et al. New COVID-19 saliva-based test: How good is it compared with the current nasopharyngeal or throat swab test? J Chin Med Assoc 2020;83:891–894.

80. Eduardo F de P, Corrêa L, Heller D, Daep CA, Benitez C, et al. Saliva-SARS-CoV-2 load reduction with mouthwash use: A randomized pilot clinical trial. Helyon 2021;7:e07346.

81. Seneviratne CJ, Balan P, Ko KKK, Udawatte NS, Lai D, et al. Efficacy of commercial mouth-rinse on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore. Infection 2021;49:305–311.

82. Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, et al. Clinical evaluation of self-collected saliva by quantitative reverse transcription-PCR (RT-qPCR), direct RT-qPCR, reverse transcription–loop-mediated isothermal amplification, and a rapid antigen test to diagnose COVID-19. J Clin Microbiol 2020;58:e01438-20.

83. Kandel C, Zheng J, McCready J, Serbanescu MA, Racher H, et al. Detection of SARS-cov-2 from saliva as compared to nasopharyngeal swabs in outpatients. Viruses 2020;12:11.

84. Vaz SN, Santana D de, Netto EM, Pedroso C, Wang W-K, et al. Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection. Braz J Infect Dis 2020;24:422–427.

85. Byrne RL, Kay GA, Kontogianni K, Brown L, Collins AM, et al. Saliva offers a sensitive, specific and non-invasive alternative to upper respiratory swabs for SARS-CoV-2 diagnosis. medRxiv 2020:2020.07.09.20149344.

86. Matic N, Stefanovic A, Leung V, Lawson T, Ritchie G, et al. Practical challenges to the clinical implementation of saliva for SARS-CoV-2 detection. Eur J Clin Microbiol Infect Dis 2021;40:447–450.

87. Barat B, Das S, De Giorgi V, Henderson DK, Kopka S, et al. Pooled Saliva Specimens for SARS-CoV-2 Testing. J Clin Microbiol 2021;59:e02486-20.

88. Ji X, Wang M, Li L, Chen F, Zhang Y, et al. The Impact of Repeated Freeze-Thaw Cycles on the Quality of Biomolecules in Four Different Tissues. Biopreserv Biobank 2017;15:475–483.

89. Centers for Disease Control and Prevention. Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing; 2021. https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html#shipping-specimens

90. Higgins TS, Wu AW, Ting JY. SARS-CoV-2 Nasopharyngeal Swab Testing-FALSE-Negative Results From a Pervasive Anatomical Misconception. JAMA Otolaryngol Head Neck Surg 2020;146:993–999.

91. Wylie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, et al. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. N Engl J Med 2020;383:1283–1286.

92. Savela ES, Winnett A, Romano AE, Porter MK, Shelby N, et al. SARS-cov-2 is detectable using sensitive RNA saliva testing days before viral load reaches detection range of low-sensitivity nasal swab tests. medRxiv 2021;2021.04.02.21254771 [Preprint].

93. Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med 2020;58:1070–1076.

94. Vandenberg O, Martiny D, Rochas O, van Beikum A, Kozlakidiz S. Considerations for diagnostic COVID-19 tests. Nat Rev Microbiol 2021;19:171–183.

95. Wang W, Xu Y, Gao R, Lu R, Han K, et al. Detection of SARS- CoV-2 in Different Types of Clinical Specimens. JAMA 2020;323:1834–1844.

96. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. Ann Intern Med 2020;173:262–267.

97. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspecrive. Eur Respir J 2020;55:2000607.

98. Zhu J, Guo J, Xu Y, Chen X. Viral dynamics of SARS-CoV-2 in saliva from infected patients. J Infect 2020;81:e68–e50.

99. Bhattacharya D, Parai D, Rout UK, Nanda RR, Kanungo S, et al. Saliva as a Potential Clinical Specimen for Diagnosis of SARS-CoV-2. SSRN Journal 2020.

100. Fernández-González M, Aguillo-V. de la Rica A, Infante A, Carvajal M, et al. Performance of Saliva Specimens for the Molecular Detection of SARS-CoV-2 in the Community Setting: Does Sample Collection Method Matter? J Clin Microbiol 2021;59:e00330-20.

101. Pasomsub E, Watcharananan SP, Watthanaschokchai T, Rakmanee K, Tassaneetrithep B, et al. Saliva sample pooling for the detection of SARS-CoV-2. J Med Virol 2021;93:1506–1511.

102. Watkins AE, Fenichel EP, Weinberger DM, Vogels CBF, Brackney DE, et al. Pooling saliva to increase SARS-CoV-2 testing capacity. medRxiv 2020:2020.2020.

103. NHS. How you get your coronavirus (COVID-19) test result; 2021. https://www.nhs.uk/conditions/coronavirus-covid-19/testing/test-results/how-you-get-your-test-result/

104. Yamazaki W, Matsumura Y, Thongchankaew-Seo U, Yamazaki Y, Nagao M. Development of a point-of-care test to detect SARS-CoV-2 from saliva which combines a simple RNA extraction method with colorimetric reverse transcription loop-mediated isothermal amplification detection. J Clin Virol 2021;136:104760.

105. Azzi L, Maurino V, Baj A, Dani M, d’Auito A, et al. Diagnostic Saliva-Tests for SARS-CoV-2. J Dent Res 2020;100:115–123.

106. Lalii MA, Langmade SJ, Chen X, Fronick CC, Sawyer CS, et al. Rapid and extraction-free detection of SARS-cov-2 from saliva by colorimetric reverse-transcription loop-mediated isothermal amplification. Clin Chem 2020;67:415–424.
107. Janíková M, Hodosy J, Boor P, Klempa B, Celec P. Loop-mediated isothermal amplification for the detection of SARS-CoV-2 in saliva. *Microb Biotechnol* 2021;14:307–316.

108. Taki K, Yokota I, Fukumoto T, Iwasaki S, Fujisawa S, et al. SARS-CoV-2 detection by fluorescence loop-mediated isothermal amplification with and without RNA extraction. *J Infect Chemother* 2021;27:410–412.

109. Food US, Administration D. Xpert® Xpress SARS-CoV-2; 2021. https://www.fda.gov/media/136314/download

110. Vaz SN, Santana DS de, Netto EM, Wang W-K, Brites C. Validation of the GeneXpert Xpress SARS-CoV-2 PCR assay using saliva as biological specimen. *Braz J Infect Dis* 2021;25:101543.

111. Azzi L, Baj A, Alberio T, Lualdi M, Veronesi G, et al. Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2: A diagnostic accuracy study. *J Infect* 2020;81:e75–e78.

112. Kashiwagi K, Iishi Y, Aoki K, Yagi S, Maeda T, et al. Immunochromatographic test for the detection of SARS-CoV-2 in saliva. *J Infect Chemother* 2021;27:384–386.

113. Mak GC, Cheng PK, Lau SS, Wong KK, Lau CS, et al. Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. *J Clin Virol* 2020;129:104500.

114. Agüillo V, Fernández-González M, Tabla V, Gonzalo-Jiménez N, García JA, et al. Evaluation of the rapid antigen test panbioCOVID-19 in saliva and nasal swabs in a population-based point-of-care study. *J Infect* 2020:30768–4.

115. Uwamino Y, Nagata M, Aoki W, Nakagawa T, Inose R, et al. Accuracy of rapid antigen detection test for nasopharyngeal swab specimens and saliva samples in comparison with RT-PCR and viral culture for SARS-CoV-2 detection. *J Infect Chemother* 2021;27:1058–1062.

116. Corman VM, Haagé VC, Bleicker T, Schmidt ML, Mühlemann B, et al. Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study. *Lancet Microbe* 2021;2:e311–e319.

117. Pray IW, Ford L, Cole D, Lee C, Bigouette JP, et al. Performance of an Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses - Wisconsin, September–October 2020. *MMWR Morb Mortal Wkly Rep* 2021;69:1642–1647.

118. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, et al. Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance. *medRxiv* 2020:2020.06.22.20136309.

119. Peto T. UK COVID-19 Lateral Flow Oversight Team. COVID-19: Rapid Antigen detection for SARS-CoV-2 by lateral flow assay: a national systematic evaluation for mass-testing. *medRxiv* 2021:2 021:01.13:21249563.

120. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. *Sci Immunol* 2020;5:52.

121. Randag PR, Pisanic N, Kruczynski K, Manabe YC, Thomas D, et al. *Infectious Diseases (except HIV/AIDS)* 2020.

122. Tan SH, Allicock O, Armstrong-Hough M, Wylie AL. Saliva as a gold-standard sample for SARS-CoV-2 detection. *Lancet Respir Med* 2021;9:562–564.

123. Hanson KE, Barker AP, Hillyard DR, Gilmore N, Barrett JW, et al. Self-Collected Anterior Nasal and Saliva Specimens versus Health Care Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-CoV-2. *J Clin Microbiol* 2020;58:e01824–20.

124. Guest JL, Sullivan PS, Valentine-Groves M, Valencia R, Adam E, et al. Suitability and Sufficiency of Telehealth Clinician-Oberved, Participant-Collected Samples for SARS-CoV-2 Testing: The iCollect Cohort Pilot Study. *JMIR Public Health Surveill* 2020;6:e19105.

125. Valentine-Groves M, Hall E, Guest JL, Adam E, Valencia R, et al. At-home self-collection of saliva, oropharyngeal swabs and dried blood spots for SARS-CoV-2 diagnosis and serology: Post-collection acceptability of specimen collection process and patient confidence in specimens. *PLoS ONE* 2020;15:e0236775.

126. Sullivan PS, Sailey C, Guest JL, Guarner J, Kelley C, et al. Detection of SARS-CoV-2 RNA and Antibodies in Diverse Samples: Protocol to Validate the Sufficiency of Provider-Oberved, Home-Collected Blood, Saliva, and Oropharyngeal Samples. *JMIR Public Health Surveill* 2020;6:e19106.

127. Sagredo-Olivares K, Morales-Gómez C, Altken-Saavedra J. Evaluation of saliva as a complementary technique to the diagnosis of COVID-19: a systematic review. *Med Oral Patol Oral Cir Bucal* 2021;26:e526–e532.

128. Michailidou E, Poulopoulos A, Tzimagiorgis G. Salivary diagnostics of the novel corona virus SARS-coV-2 (COVID-19). *Oral Dis* 2022;28:867–877.

129. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report - 46. WHO. 2021. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200306-sitrep-46-covid-19.pdf?sfvrsn=96b04ad_2020

130. Liu Y, Yan L-M, Wan L, Xiang T-X, Le A, et al. Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect Dis* 2020;20:656–657.

131. Meng M, Zhou X, Zhang Q, Zou J. The positive rate of saliva for the detection of 2019-nCoV and possible factors related to the sensitivity results. *J Med Virol* 2021;93:4136–4140.

132. Kojima N, Turner F, Siipnev V, Baceir A, Deming L, et al. Self-Collected Oral Fluid and Nasal Swabs Demonstrate Comparable Sensitivity to Clinician Collected Nasopharyngeal Swabs for Covid-19 Detection. *medRxiv* 2020.

133. Moreno-Contreras J, Espinoza MA, Sandoval-Jaime C, Cantú-Cuevas MA, Barón-Olivares H, et al. Saliva Sampling and Its Direct Lysis, an Excellent Option To Increase the Number of SARS-CoV-2 Diagnostic Tests in Settings with Supply Shortages. *J Clin Microbiol* 2020;58:e01659–20.

134. Goldfarb DM, Tilley P, Al-Rawahi GN, Srigley JA, Ford G, et al. Self-Collected Saline Gargle Samples as an Alternative to Health Care Worker-Collected Nasopharyngeal Swabs for COVID-19 Diagnosis in Outpatients. *J Clin Microbiol* 2021;59:e02427–20.

135. Echavarria M, Reyes NS, Rodriguez PE, Ypas M, Ricarte C, et al. Self-collected saliva for SARS-CoV-2 detection: A prospective study in the emergency room. *J Med Virol* 2021;93:3268–3272.

Five reasons to publish your next article with a Microbiology Society journal

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at microbiologyresearch.org.